Skip to main navigation
Skip to search
Skip to main content
Ariel University Home
Help & FAQ
Link opens in a new tab
English
עברית
العربية
Search content at Ariel University
Home
Profiles
Research units
Equipment
Research output
Prizes
Activities
Press/Media
Rituximab as maintenance therapy for patients with follicular lymphoma
Liat Vidal
, Anat Gafter-Gvili
, Leonard Leibovici
, Ofer Shpilberg
Research output
:
Contribution to journal
›
Review article
›
peer-review
22
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Rituximab as maintenance therapy for patients with follicular lymphoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Maintenance Therapy
100%
Overall Survival
100%
Follicular Lymphoma
100%
Rituximab
100%
Randomized Controlled Trial
50%
Maintenance Treatment
50%
Rituximab Maintenance
50%
Confidence Interval
33%
Hazard Ratio
33%
Adult Patients
16%
Chemotherapy
16%
Embase
16%
Relative Risk
16%
Should Be Given
16%
PubMed
16%
Newly Diagnosed
16%
Cochrane Library
16%
Selection Criteria
16%
Induction Treatment
16%
Conference Proceedings
16%
Fixed Effects Model
16%
Search Strategy
16%
First Author
16%
Cochrane Central Register of Controlled Trials
16%
Progression-free Survival
16%
Induction Therapy
16%
Chemotherapy Alone
16%
Issue 2
16%
Ongoing Trials
16%
Indolent Lymphoma
16%
Successful Induction
16%
Extracted Data
16%
Trial Data
16%
Anti-CD20 Monoclonal Antibody
16%
Relapsed/refractory
16%
Nursing and Health Professions
Maintenance Therapy
100%
Rituximab
100%
Follicular Lymphoma
100%
Overall Survival
66%
Confidence Interval
22%
Infusion
22%
Hazard Ratio
22%
Cochrane Library
22%
Chemotherapy
22%
Medline
11%
Progression Free Survival
11%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Follicular Lymphoma
100%
Overall Survival
66%
Randomized Controlled Trial
33%
Chemotherapy Regimens
22%
Progression Free Survival
11%
Neuroscience
Rituximab
100%
Randomized Controlled Trial
33%
Chemotherapy
22%